Ambu expands Recirculate program with bioplastic blades, shares trade steadily on OMX Copenhagen

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 17:43.

Ambu (DK0060946788) broadens its sustainability push in single-use endoscopy. The Danish medtech group announced an expansion of its Recirculate program to cover bioplastic SureSight blades for bronchoscopy, while its Class B shares continue to trade on OMX Copenhagen amid a cautious analyst backdrop. IR release via Ritzau on the Recirculate expansion

What Ambu announced on Recirculate

On 8 June 2026, Ambu disclosed that its Recirculate program, which collects and repurposes used single-use devices, now includes bioplastic SureSight blades for bronchoscopy in selected markets. Company communication via Ritzau The program aims to reduce waste footprint from single-use endoscopy devices by channeling post-use materials into high-quality plastic products, according to the announcement.

Ambu positions Recirculate as part of its broader environmental targets, which include reducing Scope 1 and Scope 2 emissions in operations and logistics. The expansion to bioplastic SureSight blades links product design choices with downstream recycling, reflecting a strategy to address hospital sustainability demands, especially in Europe and North America, where ESG procurement criteria have tightened in recent years. BCC Research profile outlining Ambu’s global footprint

Analyst sentiment and recent downgrade

Alongside the operational update, Ambu’s stock has faced a more cautious analyst tone. Investing.com recently noted that Ambu shares came under pressure after Danske Bank downgraded the stock to Sell, citing valuation concerns and execution risks in scaling single-use endoscopy volumes. Investing.com report on the Danske Bank downgrade The downgrade illustrates how sustainability initiatives are being weighed against profitability and growth visibility by Nordic equity research desks.

Despite the Sell rating from Danske Bank, Ambu remains followed by several European brokers focused on medtech and healthcare equipment. Consensus data compiled by MarketScreener shows a mix of Hold and Buy recommendations with a spread in price targets, reflecting differing views on the pace at which single-use bronchoscopy and ENT scopes will be adopted versus reusable systems in key markets. MarketScreener consensus overview on Ambu

The product behind the sustainability push

Ambu’s SureSight line consists of single-use blades for bronchoscopes designed to improve visibility and ease of use during airway procedures. The newly included bioplastic SureSight blades in the Recirculate program show how Ambu ties product innovation in disposable devices to circular-material initiatives, targeting hospitals that prioritize infection control together with reduced environmental impact.

Where the stock trades today

The Ambu shares (DK0060946788) last traded on OMX Copenhagen on 2026-06-25 at approximately 125.00 Danish kroner, based on recent exchange data from the Copenhagen market.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources considered reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.